A Brief Review of SPINK1 Studies

Latai Ga

doi:10.54097/ijbls.v4i1.14

Authors

Latai Ga

DOI:

https://doi.org/10.54097/ijbls.v4i1.14

Keywords:

Human Serine Protease Inhibitor, Kazal Type 1, Inhibito, Pancreatitis

Abstract

SPINK1, a trypsin inhibitor secreted by the pancreas, is closely associated with the development of pancreatitis. Additionally, SPINK1 exhibits multiple biological functions, acting as a trypsin inhibitor, a growth factor-like protein, and a negative regulator of autophagy. This paper reviews the role of the SPINK1 gene and its variants in pancreatitis development, its expression as TATI in cancer, and its role in oncogenesis.

Downloads

Download data is not yet available.

References

McMahon B, Kwaan H C. The Plasminogen Activator System and Cancer[J]. Pathophysiology of Haemostasis and Thrombosis, 2007, 36(3–4): 184–194.

Cohn J A, Mitchell R M, Jowell P S. The impact of cystic fibrosis and PSTI/SPINK1 gene mutations on susceptibility to chronic pancreatitis[J]. Clinics in Laboratory Medicine, 2005, 25(1): 79–100.

Horii A, Kobayashi T, Tomita N, et al. Primary structure of human pancreatic secretory trypsin inhibitor (PSTI) gene[J]. Biochemical and Biophysical Research Communications, 1987, 149(2): 635–641.

Bartelt D C, Shapanka R, Greene L J. The primary structure of the human pancreatic secretory trypsin inhibitor. Amino acid sequence of the reduced S-aminoethylated protein[J]. Archives of Biochemistry and Biophysics, 1977, 179(1): 189–199.

Muller N, Sarantitis I, Rouanet M, et al. Natural history of SPINK1 germline mutation related-pancreatitis[J]. EBioMedicine, 2019, 48: 581–591.

Kume K, Masamune A, Kikuta K, et al. [-215G>A; IVS3+2T>C] mutation in the SPINK1 gene causes exon 3 skipping and loss of the trypsin binding site[J]. Gut, 2006, 55(8): 1214.

Teich N, Bauer N, Mössner J, et al. Mutational screening of patients with nonalcoholic chronic pancreatitis: identification of further trypsinogen variants[J]. The American Journal of Gastroenterology, 2002, 97(2): 341–346.

Witt H, Luck W, Hennies H C, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis[J]. Nature Genetics, 2000, 25(2): 213–216.

Pfützer R H, Barmada M M, Brunskill A P, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis[J]. Gastroenterology, 2000, 119(3): 615–623.

Threadgold J, Greenhalf W, Ellis I, et al. The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease[J]. Gut, 2002, 50(5): 675–681.

Jones T E, Bellin M D, Yadav D, et al. The histopathology of SPINK1-associated chronic pancreatitis[J]. Pancreatology, 2020, 20(8): 1648–1655.

Jalaly N Y, Moran R A, Fargahi F, et al. An Evaluation of Factors Associated With Pathogenic PRSS1, SPINK1, CTFR, and/or CTRC Genetic Variants in Patients With Idiopathic Pancreatitis[J]. American Journal of Gastroenterology, 2017, 112(8): 1320–1329.

Bourgault J, Abner E, Manikpurage H D, et al. Proteome-Wide Mendelian Randomization Identifies Causal Links Between Blood Proteins and Acute Pancreatitis[J]. Gastroenterology, 2023, 164(6): 953-965.e3.

Masamune A, Kume K, Shimosegawa T. Differential roles of the SPINK1 gene mutations in alcoholic and nonalcoholic chronic pancreatitis[J]. Journal of Gastroenterology, 2007, 42 Suppl 17: 135–140.

Stenman U H, Huhtala M L, Koistinen R, et al. Immunochemical demonstration of an ovarian cancer-associated urinary peptide[J]. International Journal of Cancer, 1982, 30(1): 53–57.

Itkonen O, Stenman U-H. TATI as a biomarker[J]. Clinica Chimica Acta, 2014, 431: 260–269.

Tomlins S A, Rhodes D R, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers[J]. Cancer Cell, 2008, 13(6): 519–528.

Zhang X, Yin X, Shen P, et al. The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis[J]. OncoTargets and Therapy, 2017, 10: 3123–3130.

Pagliarulo V, Bracarda S, Eisenberger M A, et al. Contemporary role of androgen deprivation therapy for prostate cancer[J]. European Urology, 2012, 61(1): 11–25.

Tiwari R, Manzar N, Bhatia V, et al. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer[J]. Nature Communications, 2020, 11(1): 384.

Scheving L A. Primary amino acid sequence similarity between human epidermal growth factor-urogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family[J]. Archives of Biochemistry and Biophysics, 1983, 226(2): 411–413.

Singh D, Attri B K, Gill R K, et al. Review on EGFR Inhibitors: Critical Updates[J]. Mini Reviews in Medicinal Chemistry, 2016, 16(14): 1134–1166.

Ateeq B, Tomlins S A, Laxman B, et al. Therapeutic Targeting of SPINK1-Positive Prostate Cancer[J]. Science Translational Medicine, 2011, 3(72).